Effectiveness of Stellate Ganglion Block in Individuals With Parkinson's Disease

NANot yet recruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

March 31, 2024

Primary Completion Date

June 30, 2024

Study Completion Date

June 30, 2024

Conditions
Parkinson Disease
Interventions
PROCEDURE

Injection

The percutaneous approach via the paratracheal route was used for Stellate ganglion block . The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.

DRUG

Lidocaine hydrochloride

the patients were provided with Stellate ganglion block , using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block . The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.

All Listed Sponsors
lead

Muhammad

OTHER

NCT06301724 - Effectiveness of Stellate Ganglion Block in Individuals With Parkinson's Disease | Biotech Hunter | Biotech Hunter